Management
You are here

Dr. Jean-Paul Kress
Chief Executive Officer
Biography
Dr. Jean-Paul Kress
Chief Executive Officer
Year of Birth | 1965 |
Nationality | French |
Management Board Member of MorphoSys AG since | 2019 |
End of current appointment | 2022 |
Dr. Jean-Paul Kress joined MorphoSys in September 2019. He has a strong track record of commercial and (operational) strategic leadership in various senior management roles in North America and Europe. His focus has been on operations, corporate development and especially the commercialization of innovative products addressing unmet medical needs across diverse disease indications. Prior to joining MorphoSys, Dr. Kress served as President and Chief Executive Officer at Syntimmune, a clinical-stage biotechnology company developing differentiated drug candidates in a wide range of autoimmune diseases, which was acquired by Alexion in November 2018. Among other assignments, he was Executive Vice President, President of International and Head of Global Therapeutic Operations at Biogen, and Senior Vice President, Head of North America at Sanofi Genzyme, where he was instrumental in launching Dupilumab, the first biologic agent approved in atopic dermatitis. Previously, he was President and Chief Executive Officer of Sanofi Pasteur MSD, and gained further experience in positions at Gilead, Abbvie and Eli Lilly.
Dr. Kress received an M.D. degree from Faculté Necker-Enfants Malades in Paris, and graduate and post-graduate degrees in biochemistry and in molecular and cellular pharmacology from Ecole Normale Supérieure in Paris.
MEMBERSHIPS IN STATUTORY SUPERVISORY BOARDS AND/OR IN COMPARABLE DOMESTIC OR FOREIGN SUPERVISORY BODIES OF COMMERCIAL ENTERPRISES
Erytech Pharma SA, Lyon, France (publicly listed Company) | Chairman of the Board of Directors |

Sung Lee
Chief Financial Officer
Biography
Sung Lee
Chief Financial Officer
Year of Birth | 1970 |
Nationality | American |
Management Board Member of MorphoSys AG since | 2021 |
End of current appointment | 2024 |
Sung Lee came to MorphoSys in February 2021 and leads all corporate finance functions of the company.
Sung Lee has more than 20 years of finance leadership experience in biopharmaceutical and technology businesses. He joined MorphoSys from Sangamo Therapeutics, Inc., where he served as Chief Financial Officer. Prior to that role, Mr. Lee spent nearly 14 years at Gilead Sciences where he most recently led the global Financial Planning & Analysis and Investor Relations functions.
Lee started his career in the tax advisory business at PriceWaterhouseCoopers LLP. He received a Master of Business Taxation from the University of Southern California and a B.A. in Economics from the University of California, Irvine.
Memberships in statutory supervisory boards and/or in comparable domestic or foreign supervisory bodies of commercial enterprises
None

Charlotte Lohmann
SVP General Counsel
Biography
Charlotte Lohmann
SVP General Counsel
Charlotte Lohmann joined MorphoSys in May 2012. She is a very experienced lawyer with more than 20 years of professional practice, having worked in both top tier international audit and law firms as well as in publicly listed biotech companies.
She is an accomplished executive that has established solution-oriented legal departments with a focus on performance, effectiveness and making the legal department a true business partner. She has been successful in setting up and executing international projects as well as public listings on Frankfurt Stock Exchange and Nasdaq and has vast experience in advising management and supervisory boards (both as General Counsel and supervisory board member).
Prior to joining MorphoSys she worked for Wilex AG as Sr. VP Legal Affairs & Human Resources and for KPMG as Corporate Lawyer.
Charlotte Lohmann holds a Law Degree from the University of Munich and is an accredited lawyer in Germany.

Dr. Malte Peters
Chief Research and Development Officer
Biography
Dr. Malte Peters
Chief Research and Development Officer
Year of Birth | 1962 |
Nationality | German |
Management Board Member of MorphoSys AG since | 2017 |
End of current appointment | 2022 |
Dr. Peters joined MorphoSys from Sandoz International, Holzkirchen, Germany, where he was Global Head of Clinical Development of the Biopharmaceuticals Business Unit. Prior to this position, he served as Clinical Head and Site Head for Basel and East Hanover in the department of Oncology Translational Medicine at Novartis. Dr. Peters held teaching appointments in Internal Medicine and Biochemistry at the University of Mainz, Germany.
Dr. Peters received his MD degree from the Freie Universität Berlin, Germany, and was trained at the Universities of Padova, Italy and Bochum and Berlin, Germany. After scientific work at different universities he received his habilitation in Internal Medicine at the University of Mainz, Germany. Subsequently, he served as Research Scientist at the Amgen Research Institute in Toronto, Canada, as Director of Cancer Research at Merck KgaA in Darmstadt, Germany and as Medical Director at Micromet AG in Munich, Germany.
Memberships in statutory supervisory boards and/or in comparable domestic or foreign supervisory bodies of commercial enterprises
Tango Therapeutics, Cambridge, MA, U.S. (not publicly listed company; group mandate) | Member of the Board of Directors |

Dr. Barbara Krebs-Pohl
SVP, Global Head of BD&L and Alliance Management
Biography
Dr. Barbara Krebs-Pohl
SVP, Global Head of BD&L and Alliance Management
Dr. Barbara Krebs-Pohl is a highly regarded business development executive with an outstanding track record of accomplishment of revenues and forging successful alliances with pharma and biotechnology companies worldwide.
Since joining MorphoSys in 1998, Dr. Krebs-Pohl has successfully led R&D teams, international alliances and negotiation teams spanning a broad variety of deal structures. She has been instrumental in program search & evaluation, portfolio strategy and a multitude of transactions, including the in-licensing of tafasitamab from Xencor, the long-term HuCAL alliance with Novartis and the co-development and co-commercialization partnership with Incyte. She is also the winner of the "Astra Zeneca Business Development Executive of the Year 2013" Award.
Prior to joining MorphoSys, Dr. Krebs-Pohl earned the opportunity to work with Nobel Prize winner Sir Greg Winter at MRC/LMB Cambridge, UK. She holds a PhD from the University of Mainz in Immunology, theoretical Physics and Biochemistry. She is a Master of Science (MSc) Chemistry from the University of Cologne and further trained at the RWTH Aachen University with focus on Medical Biology and Bacteriology.

Dr. Roland Wandeler
Chief Operating Officer
Biography
Dr. Roland Wandeler
Chief Operating Officer
Year of Birth | 1972 |
Nationality | Swiss |
Management Board Member of MorphoSys AG since | 2020 |
End of current appointment | 2023 |
Dr. Roland Wandeler joined MorphoSys in May 2020. He has more than 15 years of commercial leadership and general management experience in the pharmaceutical and biotechnology industry, with a strong track record of building and leading sizable affiliates and U.S. franchises across multiple therapeutic areas, including oncology and hematology. Prior to MorphoSys, Dr. Wandeler held positions of increasing responsibility at Amgen, Inc., including General Manager Germany in Munich and General Manager Spain & Portugal in Barcelona, before most recently serving as Corporate Vice President and General Manager of Amgen’s US Bone Health and Cardiology Business Unit in Thousand Oaks, California. Dr. Wandeler initially joined Amgen in 2006 in strategic planning for its international business. Subsequent highlights include sales and business unit leadership roles in Germany at the time of several launches across therapeutic areas. Dr. Wandeler began his career at Boston Consulting Group (BCG) in Zurich, Switzerland and Los Angeles, California, where he was a core member of BCG’s global Healthcare Practice as well as a Member of the Zurich and Los Angeles Management Teams.
Dr. Wandeler holds a M.Sc. in Chemical Engineering and a Doctorate in Technical Sciences from ETH Zurich.
MEMBERSHIPS IN STATUTORY SUPERVISORY BOARDS AND/OR IN COMPARABLE DOMESTIC OR FOREIGN SUPERVISORY BODIES OF COMMERCIAL ENTERPRISES
No other memberships.

Maria Castresana
SVP Global Head of Human Resources
Biography
Maria Castresana
SVP Global Head of Human Resources
Maria Castresana is a global HR Executive with extensive international experience in the pharmaceutical and chemical industry gained over more than 20 years of professional experience in Spain, Germany and the USA.
Prior to joining MorphoSys in 2020, Maria Castresana held positions of increasing responsibility at Boehringer Ingelheim, a global pharmaceutical player that expanded in recent years into oncology and specialty. She lately served as Global Head of Talent, Leadership & Organizational Effectiveness. Among other assignments, she was Global Business Partner for Consumer Health Care and led the carve-out and sale of the business in the frame of BI's and Sanofi's SWAP of CHC and Animal Health business, which closed on January 1st, 2017. Furthermore, she spent several years in the USA and was instrumental in the set-up of new commercial launch teams for Oncology, Diabetes and Cardiovascular.
Previously, she also worked for Ecolab as European Compensation Manager and gained early experience at Bayer.
Maria Castresana received a Law Degree and a Business Administration Degree from the University of Deusto in Spain and a Master in Human Resources from Rutgers University in the USA.

Daniel Palmacci
SVP Global Head of Technical Operations
Biography
Daniel Palmacci
SVP Global Head of Technical Operations
Daniel Palmacci brings over 20 years of experience in the international pharmaceutical industry with responsibility for Manufacturing, Supply Chain and Operational Excellence, leading cross-functional teams responsible for Pharmaceutical cGMP Production of Biologics API and sterile Fill & Finish, Manufacturing Science & Technology and Launch Management of new biotech products and biosimilars.
Before joining MorphoSys he has been working in various senior roles at MSD and Novartis in Germany, Austria and Switzerland. He spent many years in the United States, where he was responsible for the construction of the new cGMP certified biopharmaceutical facility at Schering AG, Seattle. Later Daniel took over the responsibility for a biopharmaceutical manufacturing facility for BayerHealthCare in the United States. He has a wide multicultural experience through international assignments in Germany, Italy, India, Brazil and the US.
Daniel holds a master’s degree in Chemistry and Process Engineering from the University of Berlin.

Dr. Marc Cluzel
Chairman
Biography and additional memberships
Dr. Marc Cluzel
Chairman
Year of birth | 1955 |
Nationality | French |
Place of residence | Montpellier, France |
Initial appointment | 2012 |
End of current period | 2021 |
Professional Development
Currently |
Member of the Supervisory Board of MorphoSys AG as well as member of comparable foreign supervisory board of a commercial enterprise (see below) |
2011 – 2012 |
Executive Vice President of Product Development, HÙYÀ Bioscience International, LLC, San Diego, CA, USA |
2009 - 2010 |
Executive Vice President of Research & Development, Sanofi-Aventis S.A., Paris, France |
2007 – 2009 |
Senior Vice President of Science and Medical Affairs, Sanofi-Aventis S.A., Paris, France |
2002 – 2011 |
Chairman and CEO, Sanofi-Aventis R&D France, Paris, France |
1996 – 2001 |
Head of Project Direction, Sanofi R&D France, Paris, France |
1993 – 1996 |
Project Director, Sanofi R&D France, Paris, France |
1991 – 1993 |
Clinical Pharmacologist, Sanofi R&D France, Montpellier, France |
Education
1983 – 1990 |
Ph.D. Biochemistry at University of Montpellier, France |
1973 – 1985 |
M.D., Study of Medicine at University of Montpellier, France |
Memberships in statutory supervisory boards and/or in comparable domestic or foreign supervisory bodies of commercial enterprises
Moleac Pte. Ltd., Singapore* |
Member of the Board of Directors |
Griffon Pharmaceuticals Inc., Montreal Canada* |
Member of the Board of Directors |
*not publicly listed company; group mandate
As of February 2021

Dr. George Golumbeski
Deputy Chairman
Biography and additional memberships
Dr. George Golumbeski
Deputy Chairman
Year of birth | 1957 |
Nationality | US-American |
Place of residence | Far Hills, NJ, USA |
Initial appointment | 2018 |
End of current period | 2023 |
Professional Development
Since 2018 |
Business consultant in the life sciences and healthcare industries |
2018 - 2019 |
President, Grail Inc., Menlo Park, CA, USA |
2017 – 2018 |
Executive Vice President & Executive Advisor for Innovation, Celgene Corporation, Summit, NJ, USA |
2009 – 2017 |
Executive Vice President, Business Development, Celgene Corporation, Summit, NJ, USA |
2008 – 2009 |
Chief Executive Officer, Nabriva Therapeutics AG, Vienna, Austria |
2002 – 2008 |
Vice President, Business Development, Licensing & Strategy, Novartis Oncology, Florham Park, NJ, USA |
2001 – 2002 |
Vice President, R&D Business Development, Elan Biopharmaceuticals, San Diego, CA, USA |
2000 – 2001 |
Senior Director, Licensing, EMD Pharmaceuticals, Durham, NC, USA |
1997 – 2000 |
Vice President / Director, Corporate Development, Schwarz Pharma, Mequon, WI, USA |
1996 – 1997 |
Director, Business Development, Pierce Chemical Company, Rockford, IL, USA |
1991 – 1995 |
Technology Acquisition Manager / Group Leader, Research & Development / Group Leader, Diagnostics Research & Development, Promega Corporation, Madison, WI, USA |
Education
1985 |
Ph.D., Genetics, University of Wisconsin-Madison, Madison, WI, USA |
1986 – 1991 |
Postdoctoral Research, Molecular biology, University of Colorado Boulder, Boulder, CO, USA |
1997 |
B.A., Biology, University of Virginia, Charlottesville, VA, USA |
Memberships in statutory supervisory boards and/or in comparable domestic or foreign supervisory bodies of commercial enterprises
Carrick Therapeutics Ltd., Dublin, Ireland* |
Chairman of the Board of Directors |
Sage Therapeutics, Cambridge, MA, USA (publicly listed company) |
Member of the Board of Directors |
Shattuck Labs, Inc., Austin, TX, USA* |
Member of the Board of Directors |
* not publicly listed company; group mandate

Wendy Johnson
Member
Biography and additional memberships
Wendy Johnson
Member
Year of birth | 1952 |
Nationality | US-American |
Place of residence | San Diego, CA, USA |
Initial appointment | 2015 |
End of current period | 2022 |
Professional Development
Currently |
Chief Development Officer, Reneo Pharmaceuticals, San Diego, CA, USA; |
2007 – 2014 |
Founder, President and CEO, Aires Pharmaceuticals, Inc., San Diego, |
2005 – 2014 |
Venture Partner, ProQuest Investments, San Diego, CA, USA |
2001 – 2005 |
Senior Vice President Corporate Development, Salmedix, Inc., San Diego, CA, USA |
2000 – 2001 |
Independent Consultant, San Diego, CA, USA |
2000 – 1998 |
Vice President Business Development, Women First HealthCare, San Diego, CA, USA |
1998 – 1994 |
Vice President Corporate Development & Operations, Selective Genetics, San Diego, CA, USA |
1994 – 1990 |
Vice President Business Development & Regulatory Affairs, Cytel Corp., San Diego, CA, USA |
1990 – 1988 |
Manager Business Development, Synbiotics Corp., San Diego, CA, USA |
1988 – 1986 |
International Business Development & Regulatory Affairs Manager, Murex Corp., Cambridge, Great Britain |
1986 – 1976 |
Assistant Director, US Food & Drug Administration, Center for Devices & Radiological Health, Rockville, MD, USA |
Education
1986 – 1984 |
M.B.A., Loyola Marymount University, Los Angeles, CA, USA |
1976 – 1974 |
M.S. Clinical Microbiology, Hahnemann University Hospital, Philadelphia, PA, USA |
1974 – 1970 |
B.S. Microbiology, University of Maryland, College Park, MD, USA |
Memberships in statutory supervisory boards and/or in comparable domestic or foreign supervisory bodies of commercial enterprises
Exagen, Inc., Vista, CA, USA |
Member of the Board of Directors |
* not publicly listed company; group mandate
As of February 2021

Krisja Vermeylen
Member
Biography and additional memberships
Krisja Vermeylen
Member
Year of birth | 1962 |
Nationality | Belgian |
Place of residence | Herentals, Belgium |
Initial appointment | 2017 |
End of current period | 2021 |
Professional Development
Currently |
Business consultant in the life science and healthcare industries |
2015 - 2018 |
Senior Vice President Corporate People & Organisation, Novo Nordisk A/S, Bagsvaerd, Denmark |
2013 – 2015 |
Corporate Vice President and General Manager (CVP), Novo Nordisk Pharma GmbH, Mainz, Germany |
2008 – 2013 |
Vice President (France & BeLux), Novo Nordisk SA, Paris, France |
2002 – 2013 |
Vice President Europe West (France, Belgium, Luxembourg, Netherlands), Novo Nordisk SA, Paris, France |
1998 – 2002 |
General Manager (BeLux & Director GHT France), Novo Nordisk SA, Brussels, Belgium |
1997 – 1998 |
Marketing & Sales Manager Diabetes/Women Health Care/Growth Hormone/Haemophilia, Novo Nordisk SA, Brussels, Belgium |
1997 |
Marketing Manager Diabetes/Women Health Care/Growth Hormone, Novo Nordisk SA, Brussels, Belgium |
1996 – 1997 |
Senior Product Manager Anaesthesia and Cardiovascular, Pharmacia & Upjohn, Brussels, Belgium |
1995 |
Product & Sales Manager Low molecular weight heparin, Pharmacia, Brussels, Belgium |
1994 – 1995 |
Product Manager Anaesthesia and Cardiovascular, Pharmacia, Brussels, Belgium |
1993 – 1994 |
Product Manager Anaesthesia, Pharmacia, Brussels, Belgium |
1991 – 1993 |
Medical Representative Hospital Division Parenteral Nutrition, Kabi Pharmacia, Brussels, Belgium |
1986 – 1991 |
Pharmacist dispenser |
Education
2015 - 2017 |
Independent Director Program (IDP) INSEAD France |
2002 |
Advanced Management Program (AMP) INSEAD France |
1985 – 1986 |
Doctoral student of bromatology at the University of Antwerp (UIA), Antwerp, Belgium |
1980 – 1985 |
Pharmacist / Master in pharmaceutical sciences at the University of Antwerp (UIA, RUCA), Antwerp, Belgium |
Memberships in statutory supervisory boards and/or in comparable domestic or foreign supervisory bodies of commercial enterprises
Diaverum AB, Lund, Sweden* |
Member of the Board of Directors |
*not publicly listed company; group mandate
As of February 2021

Michael Brosnan
Member
Biography and additional memberships
Michael Brosnan
Member
Year of birth | 1955 |
Nationality | US-American |
Place of residence | Westford, MA, USA |
Initial appointment | 2018 |
End of current period | 2023 |
Professional development
Currently |
Freelance business consultant in the life sciences and healthcare industries |
2010 - 2019 |
Chief Financial Officer, Fresenius Medical Care Management AG, Bad Homburg v.d.H, Germany |
2003 – 2009 |
Executive Vice President and Chief Financial Officer, Fresenius Medical Care North America, Waltham, MA, USA |
1999 – 2003 |
Senior Vice President of Finance, Fresenius Medical Care North America, Waltham, MA, USA |
1998 |
Vice President Finance and Administration, Spectra Renal Management, Waltham, MA, USA |
1997 |
Vice President of Financial Operations, High Voltage Engineering Corporation, Wakefield, MA, USA |
1994 – 1996 |
Senior Controller, Commercial Imaging Group, Polaroid Corporation, Cambridge, MA, USA |
1978 – 1993 |
KPMG, Boston, MA, USA, (1988 – 1993 Audit Partner) |
Education
1978 |
BSc, Business Administration, Accounting, Northeastern University, Boston, MA, USA |
NO MEMBERSHIPS IN STATUTORY SUPERVISORY BOARDS AND/OR IN COMPARABLE DOMESTIC OR FOREIGN SUPERVISORY BODIES OF COMMERCIAL ENTERPRISES
As of February 2021

Sharon Curran
Member
Biography and additional memberships
Sharon Curran
Member
Year of birth | 1968 |
Nationality | Irish |
Place of residence | Dublin, Ireland |
Initial appointment | 2019 |
End of current period | 2021 |
PROFESSIONAL DEVELOPMENT
Currently |
Non-Executive Director in life sciences and healthcare industries |
2014 – 2017 |
Vice President, Global Specialty Franchise & Customer Excellence, AbbVie, Chicago, IL, USA |
2012 – 2014 |
Vice President and Senior Director, Global Marketing Specialty, Global Marketing & Commercial Operations, AbbVie, Chicago, IL, USA |
2009 – 2012 |
Global Brand & Commercial Director, Abbott International Office, Ireland |
2002 – 2008 |
Divisional Head, Strategy & Operations, Eli Lilly, UK & Ireland |
1999 – 2002 |
Divisional Head, Primary Care Strategy & Operations, Eli Lilly, UK |
1996 – 1999 |
Group Marketing/Business Unit Manager, Eli Lilly, Dublin, Ireland |
1995 - 1996 |
Hospital Sales Specialist, Eli Lilly, Dublin, Ireland |
1993 – 1995 |
Hospital Sales Representative, Novo Nordisk, Dublin, Ireland |
1992 – 1993 |
Medical Device Sales Representative, Dublin, Ireland |
EDUCATION
2007 - 2008 |
MSc Business Administration, Trinity College Dublin, Ireland |
1989 -1992 |
BSc Biotechnology, Dublin City University, Ireland |
1986 – 1989 |
Associate of Institute of Medical Laboratory Science, DIT/ Technological University, Dublin, Ireland |
MEMBERSHIPS IN STATUTORY SUPERVISORY BOARDS AND/OR IN COMPARABLE DOMESTIC OR FOREIGN SUPERVISORY BODIES OF COMMERCIAL ENTERPRISES
CAT Capital Topco Limited, Saint Peter Port, Guernsey* |
Member of the Board of Directors |
CAT Capital Bidco Limited, Dublin, Ireland* |
Member of the Board of Directors |
Circassia Pharmaceuticals plc., Oxford, United Kingdom (publicly listed company) |
Member of the Board of Directors |
*not publicly listed company; group mandate
As of February 2021
Composition of the Supervisory Board SINCE Termination of the 2020 Annual General Meeting
Initial Appointment |
End of Current Period |
Audit Committee |
Remuneration and Nomination Committee |
Science and Technology Committee |
|
---|---|---|---|---|---|
Dr. Marc Cluzel | 2012 | 2021 | M | ||
Krisja Vermeylen | 2017 | 2021 | M | C | |
Wendy Johnson | 2015 | 2022 | M | M | |
Dr. George Golumbeski | 2018 | 2023 | C | ||
Michael Brosnan (FE) | 2018 | 2023 | C | ||
Sharon Curran | 2019 | 2021 | M | ||
FE=Independent Financial Expert C=Chairperson M=Member